How Novartis Is Making SENSE Of Clinical Data In Digital Age

The Swiss major has been showcasing its Nerve Live data analytics platform, where staff stationed at its SENSE operations center in Basel can monitor 500 or so clinical studies to predict - and stop - potential delays.

SENSE
The SENSE 'control tower' • Source: Novartis

The buzz has been deafening for years across the pharmaceutical sector about how the digital revolution is going to transform the way business is done but Novartis AG has been demonstrating a system that is already up and running and allows it to make sense of big data and manage hundreds of clinical trials worldwide from a 'control tower' in Switzerland.

CEO Vas Narasimhan repeatedly states that his vision is to create the leading medicines company in the world, powered by data and digital, and last week, ahead of Novartis' annual...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By 

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.